Page 1

2nd Quarter 2021 Results 2nd Quarter 2021 Sales Worldwide Increased $ 23.3B 27.1 % Diluted Earnings Per Share Increased $ 2.35 72.8 % Excluding acquisitions / divestitures on an operational basis Worldwide Increased 23.8 % * Adjusted Diluted Earnings Per Share * Increased | $ 2.48 48.5 % " Our second - quarter results showcase Johnson & Johnson's diversified portfolio , driven by strong sales and earnings growth across our Medical Device , Consumer Health and Pharmaceutical businesses . I'm so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world , in addition to advancing our pipeline with new product launches and regulatory submissions . These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long - term value to all of our stakeholders . " Alex Gorsky Chairman and Chief Executive Officer Johnson & Johnson $ 3.7 Billion $ 12.6 Billion B $ 7.0 Billion aff Worldwide Consumer Health Sales Consumer Health worldwide reported sales increased 13.3 % or 9.2 % operationally¹ . Primary operational drivers : Aveeno . Neutrogena Motrin IB Stelara DARZALEX imbruvică ( ustekinumab ) ( ibrutinib ) Worldwide Pharmaceutical Sales Pharmaceutical worldwide reported sales increased 17.2 % or 13.6 % operationally¹ . Primary operational drivers : Erleada Uptravi selexipag ( apalutamide omtablets tablets a 101 Surgical Vision Johnson & Johnson Contact Lens ZYRTEC LISTERINE ( daratumumab ) action for intravenous infusion 100mg / 5m 400mg / 20ml Note : values may have been rounded Knees 09x beauty pure and simple Worldwide Medical Devices Sales Medical Devices worldwide reported sales increased 62.7 % or 57.2 % operationally ' . Primary operational drivers : Hips INVEGA SUSTENNA paliperidone palmitate Spine BAND - AID BRAND ADHESIVE BANDAGES - Tremfya ( guselkumab ) Opsumit macitentan Endocutters Energy S Ⓒ Wound Closure Biosurgery Electrophysiology Trauma For full financial data and non - GAAP reconciliations , please refer to Johnson & Johnson's earnings release issued on July 21 , 2021 , available at http://www.investor.jnj.com/sales-earnings.cfm . * Non - GAAP financial measure ; non - GAAP financial measures should not be considered replacements for , and should be read together with , the most comparable GAAP financial measures . ¹Non - GAAP measure ; excludes the impact of translational currency . Caution Concerning Forward - Looking Statements : This document contains " forward - looking statements " as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance . You are cautioned not to rely on these forward - looking statements , which are based on current expectations of future events . For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions , expectations , and projections expressed in any forward - looking statements , review the " Note to Investors Concerning Forward - Looking Statements " included in the Johnson & Johnson earnings release issued on July 21 , 2021 , as well as the most recently filed Johnson & Johnson Reports on Forms 10 - K and 10 - Q . Johnson & Johnson does not undertake to update any forward - looking statement as result of new information future events or developments .